TSMC stock jumps in premarket after Goldman target hike — what investors watch before earnings

TSMC stock jumps in premarket after Goldman target hike — what investors watch before earnings

NEW YORK, Jan 5, 2026, 04:29 ET — Premarket

  • Taiwan Semiconductor’s U.S.-listed shares were up about 3.4% in premarket trading after Friday’s 5.2% jump.
  • A Goldman Sachs target raise in Taipei put fresh focus on tight advanced-chip capacity and 2026–27 growth expectations.
  • Traders are looking to TSMC’s December sales on Jan. 9 and its Jan. 15 earnings conference, with a company quiet period starting today.

Taiwan Semiconductor Manufacturing Co’s U.S.-listed shares rose about 3.4% in premarket trading on Monday, tracking a new record run in Taipei after a bullish Goldman Sachs call on the chipmaker’s artificial-intelligence outlook. Investing

The move matters because TSMC sits at the center of the global supply chain for advanced chips used in AI servers, smartphones and other high-end electronics, making its stock a bellwether for the broader semiconductor rally. Investors have been using the start of the year to reprice “AI” exposure across the sector, and TSMC’s ADR is one of the biggest liquid proxies for that trade. Investing

Timing is also tight. TSMC is days away from two closely watched updates — monthly sales for December and its fourth-quarter results — while the company enters a “quiet period” starting Monday, a standard pre-earnings blackout when management limits contact with investors. TSMC

Goldman Sachs lifted its target price on TSMC to NT$2,330 from NT$1,720 and reiterated a “conviction buy” rating, saying AI-related demand was likely to keep supply tight into 2027, Investing.com reported. In a separate summary of the note, the brokerage projected revenue growth of 30% in 2026 and 28% in 2027 in U.S. dollar terms, and said gross margin — the share of revenue left after production costs — could stay above 60% over 2026–2028. Investing

Other analysts are making a similar case. Stefan Chang and Warren Lau at Aletheia Capital wrote that even as cloud service providers — the big companies that run cloud-computing platforms — prioritize in-house ASICs (custom chips built for specific tasks), “all heavily rely on TSMC’s foundry services,” meaning contract manufacturing done for customers. Taipei Times

In the U.S., the ADR closed on Friday up 5.17% at $319.61, after trading as high as $321.59, a fresh 52-week high. Extended-hours trading showed the shares at $330.50, implying another leg higher ahead of the opening bell. Investing

TSMC has also benefited from a broader bid for chip names. Shares of ASML, a key supplier of chipmaking tools, jumped 8.8% on Friday after a double upgrade, while the Philadelphia Semiconductor Index rose about 4%, according to an Investors.com report. Investors

A legal backdrop in Taiwan remains in view. Taiwanese prosecutors said on Monday they filed additional indictments against the Taiwan unit of Tokyo Electron and three other defendants in a case involving alleged theft of TSMC trade secrets, with potential fines of up to T$120 million if convicted. Reuters

Still, the risk for TSMC bulls is that the same AI boom driving chip demand could stoke inflation and keep interest rates higher for longer, which tends to pressure richly valued technology shares. Investors have flagged AI-driven inflation as an underappreciated 2026 risk, Reuters reported, adding another macro variable as chip stocks trade near record levels. Reuters

Stock Market Today

  • Summit Therapeutics valuation under the microscope after share strength; P/B at 74.8x, DCF fair value $217.67
    January 7, 2026, 8:37 PM EST. Summit Therapeutics (SMMT) rose 1.9% on the day and 8.7% over the week, though longer-term returns remain uneven: 30 days up 2.07%, 90 days down 16.07%, and a three-year total shareholder return that highlights patient holders' gains despite near-term momentum cooling. On a P/B basis, the stock trades at 74.8x price against a US$19.01 share price, far above the industry average of 2.7x and a peer average of 11.2x, signaling the market expects a stronger future than the balance sheet implies. A DCF model puts fair value at US$217.67 versus last close of US$19.01, suggesting potential discount based on cash flow scenarios. The narrative flags OVERVALUED P/B and UNDERVALUED DCF; risk remains, including ongoing net losses of US$921.617 and potential ivonescimab trial failures.
EQT natural gas stock slips as Henry Hub futures hit late-October low; storage report ahead
Previous Story

EQT natural gas stock slips as Henry Hub futures hit late-October low; storage report ahead

SLB stock in focus before the open as oil slips on Venezuela upheaval and earnings near
Next Story

SLB stock in focus before the open as oil slips on Venezuela upheaval and earnings near

Go toTop